BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res 2016;46:1226-33. [PMID: 26866817 DOI: 10.1111/hepr.12671] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Critical Reviews in Food Science and Nutrition 2019;59:2494-505. [DOI: 10.1080/10408398.2018.1458021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
2 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 13.4] [Reference Citation Analysis]
3 Panera N, Barbaro B, Della Corte C, Mosca A, Nobili V, Alisi A. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. Nutrition Research 2018;58:1-16. [DOI: 10.1016/j.nutres.2018.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
4 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
5 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sivamaruthi, Kesika, Chaiyasut. A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics. Sci Pharm 2019;87:26. [DOI: 10.3390/scipharm87040026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
7 Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2016;17:1937-46. [DOI: 10.1080/14656566.2016.1225727] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
8 Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2019;2019:1484598. [PMID: 31885541 DOI: 10.1155/2019/1484598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
9 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
10 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver: Microbiota and the Liver. Liver Transpl 2018;24:539-50. [DOI: 10.1002/lt.25008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
11 Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019;110:139-49. [PMID: 31124558 DOI: 10.1093/ajcn/nqz042] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
12 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
13 Mansour A, Hekmatdoost A, Mirmiran P. What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease? J Dig Dis 2019;20:271-7. [DOI: 10.1111/1751-2980.12751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
15 Brecelj J, Orel R. Non-Alcoholic Fatty Liver Disease in Children. Medicina (Kaunas) 2021;57:719. [PMID: 34357000 DOI: 10.3390/medicina57070719] [Reference Citation Analysis]
16 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
17 Liu L, Li P, Liu Y, Zhang Y. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Dig Dis Sci. 2019;64:3402-3412. [PMID: 31203554 DOI: 10.1007/s10620-019-05699-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
18 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
19 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
20 Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7:1529. [PMID: 28484247 DOI: 10.1038/s41598-017-01751-y] [Cited by in Crossref: 113] [Cited by in F6Publishing: 113] [Article Influence: 22.6] [Reference Citation Analysis]
21 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
22 Braun HA, Faasse SA, Vos MB. Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment. Gastroenterol Clin North Am 2018;47:949-68. [PMID: 30337043 DOI: 10.1016/j.gtc.2018.07.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Gao X, Miao R, Zhu Y, Lin C, Yang X, Jia R, Linghan K, Wan C, Deng J. A new insight into acute lymphoblastic leukemia in children: influences of changed intestinal microfloras. BMC Pediatr 2020;20:290. [PMID: 32522199 DOI: 10.1186/s12887-020-02192-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Javadi L, Ghavami M, Khoshbaten M, Safaiyan A, Barzegari A, Pourghassem Gargari B. The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial. Iran Red Crescent Med J 2017;19. [DOI: 10.5812/ircmj.46017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 3.2] [Reference Citation Analysis]
25 Jones RB, Alderete TL, Martin AA, Geary BA, Hwang DH, Palmer SL, Goran MI. Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial. Pediatr Obes 2018;13:705-14. [PMID: 29493105 DOI: 10.1111/ijpo.12273] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
26 Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. Curr Obes Rep. 2019;8:317-332. [PMID: 31175629 DOI: 10.1007/s13679-019-00352-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 35.5] [Reference Citation Analysis]
27 Altamirano-barrera A, Uribe M, Chávez-tapia NC, Nuño-lámbarri N. The role of the gut microbiota in the pathology and prevention of liver disease. The Journal of Nutritional Biochemistry 2018;60:1-8. [DOI: 10.1016/j.jnutbio.2018.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
28 Shirvani-Rad S, Tabatabaei-Malazy O, Mohseni S, Hasani-Ranjbar S, Soroush AR, Hoseini-Tavassol Z, Ejtahed HS, Larijani B. Probiotics as a Complementary Therapy for Management of Obesity: A Systematic Review. Evid Based Complement Alternat Med 2021;2021:6688450. [PMID: 33552218 DOI: 10.1155/2021/6688450] [Reference Citation Analysis]
29 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 20.2] [Reference Citation Analysis]
31 Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 2016;1:56-67. [PMID: 28404113 DOI: 10.1016/S2468-1253(16)30011-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 31] [Article Influence: 15.2] [Reference Citation Analysis]
32 Chaves FGB, Oliveira GF, Ribeiro JP, Serafim JV, Cordeiro LFM, Alvares MA, Cecchi MT, Vasquez MC, Souza TBD, Rullo VEV. THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW. Rev Paul Pediatr 2021;39:e2019226. [PMID: 32876312 DOI: 10.1590/1984-0462/2021/39/2019226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
34 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
35 Kobyliak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, Kyriienko D, Komisarenko I, Dynnyk O. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Med. 2018;109:418-428. [PMID: 30221912 DOI: 10.23736/s0026-4806.18.05845-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
36 Zhou D, Pan Q, Liu XL, Yang RX, Chen YW, Liu C, Fan JG. Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. J Gastroenterol Hepatol. 2017;32:1640-1648. [PMID: 28109017 DOI: 10.1111/jgh.13742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
37 Liu Q, Niu CY. From "two hit theory" to "multiple hit theory": Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(19): 1171-1178 [DOI: 10.11569/wcjd.v27.i19.1171] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Zarezadeh M, Musazadeh V, Faghfouri AH, Roshanravan N, Dehghan P. Probiotics act as a potent intervention in improving lipid profile: An umbrella systematic review and meta-analysis. Crit Rev Food Sci Nutr 2021;:1-14. [PMID: 34817299 DOI: 10.1080/10408398.2021.2004578] [Reference Citation Analysis]
39 Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN 2020;39:53-60. [PMID: 32859329 DOI: 10.1016/j.clnesp.2020.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Cai GS, Su H, Zhang J. Protective effect of probiotics in patients with non-alcoholic fatty liver disease.Medicine (Baltimore). 2020;99:e21464. [PMID: 32769877 DOI: 10.1097/MD.0000000000021464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
41 Michels N, Zouiouich S, Vanderbauwhede B, Vanacker J, Indave Ruiz BI, Huybrechts I. Human microbiome and metabolic health: An overview of systematic reviews. Obes Rev 2022;:e13409. [PMID: 34978141 DOI: 10.1111/obr.13409] [Reference Citation Analysis]